---
title: 'Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory
  diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related
  Diseases Registry project'
date: '2024-04-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38633125/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240418180524&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Polatuzumab vedotin (Pola) is an approved therapy in combination with
  rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma
  (RR-DLBCL) based on positive results of the landmark phase II randomised G029365
  trial. However, trial results for many approved novel therapies in RR-DLBCL have
  not been replicated in routine care cohorts, as RR-DLBCL patient populations are
  heterogeneous and trial eligibility is increasingly restrictive. We evaluated outcomes
  from pola ...
disable_comments: true
---
Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial results for many approved novel therapies in RR-DLBCL have not been replicated in routine care cohorts, as RR-DLBCL patient populations are heterogeneous and trial eligibility is increasingly restrictive. We evaluated outcomes from pola ...